• Ticker

DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

$50.87 $0.37 (0.73%)

REAL-TIME: Last trade at

Salix Pharmaceuticals, Ltd.

NASDAQ:SLXP

Friday's Bio Pharma Potential Catalyst Price Movers

Bio-Pharma Stocks To Watch For Next Week

Don't Get Too Worked Up Over Salix Pharmaceuticals' Latest Numbers

Duke Realty Leases to Novella - Analyst Blog

Salix Pharmaceuticals Beats on Both Top and Bottom Lines

Could The Small Cap Healthcare ETF Be A Great Pick? - ETF News And Commentary

Salix Beats; Ups EPS Outlook - Analyst Blog

Salix Faces Regulatory Delays - Analyst Blog

Vivus Wins FDA Approval

The Zacks Analyst Blog Highlights: US Airways Group, United Continental Holdings, Delta Airlines, Sa

Back to Neutral on Salix - Analyst Blog

1 Reason Salix Pharmaceuticals May Be Headed for a Slowdown

Salix Pharmaceuticals Beats Up on Analysts Yet Again

Salix Beats, Provides Mixed Guidance - Analyst Blog

Salix Scores with Oral Relistor - Analyst Blog

US Stock Futures: HOT STOCKS TO WATCH

US Stock Futures: HOT STOCKS TO WATCH

Salix Pharmaceuticals Shares Popped: What You Need to Know

Salix Pharmaceuticals - Aggressive Growth

Salix Pharmaceuticals (SLXP) - Bull of the Day

Zacks Bull and Bear of the Day Highlights: Salix Pharmaceuticals, Montpelier Re Holdings, Wal-Mart,

Panel Recommends Salix Study Design - Analyst Blog

Don't Get Too Worked Up Over ViroPharma's Latest Numbers

Let's Check Salix Pharmaceuticals' Growth

Salix Pharmaceuticals Earnings Preview

One Reason the Street Should Expect Big Things From Salix Pharmaceuticals

The 20 Fastest Growers in Pharma

The 9 Top Value-Creating Pharmaceutical Companies

Is ViroPharma Going to Burn You?

1 Reason the Street Should Expect Big Things From ViroPharma

Is Salix Pharmaceuticals Hiding Weakness?

Candy Maker Nestle Bids $1 Billion to Study Stomach Problems

Rebound Ideas: 3 Beaten-Down Stocks With Significant Cash Holdings

How to Maneuver the Biotech Sector

Extreme Pessimism: 19 Stocks Near Lows With Analyst Rating Downgrades

Neutral on Salix

4 Stocks Facing Bearish Momentum With Excellent Growth Prospects

11 Oversold Companies With Enough Cash to Cover 1+ Years of Operating Expenses

Salix To Seek FDA Meeting To Discuss Expanded Xifaxan Use

30 Oversold Stocks Being Snapped Up by Mutual Funds

See More Articles...